KOCAA
ACAD icon

Knights of Columbus Asset Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History

Knights of Columbus Asset Advisors’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-17,125
Closed -$724K – 323
2020
Q1 		$724K Buy
+17,125
New +$706K 0.09% 282

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Knights of Columbus Asset Advisors's ACAD Position: Q2 2020 in Review

Knights of Columbus Asset Advisors sold out of Acadia Pharmaceuticals (ACAD) in Q2 2020, closing a stake of 17,125 shares — an estimated $724K sold.

Knights of Columbus Asset Advisors first reported a position in ACAD in Q1 2020 and held it in 1 quarter. The position peaked at $724K in Q1 2020. 298 funds tracked by Wall St. Rank hold ACAD as of Q2 2020.

  • Knights of Columbus Asset Advisors reported no remaining Acadia Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • Knights of Columbus Asset Advisors sold 17,125 Acadia Pharmaceuticals shares in Q2 2020, an estimated $724K.
  • Knights of Columbus Asset Advisors first reported a position in Acadia Pharmaceuticals in Q1 2020 and held it in 1 quarter.
  • Knights of Columbus Asset Advisors's Acadia Pharmaceuticals position peaked at $724K in Q1 2020.
  • 298 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2020.

Based on Knights of Columbus Asset Advisors's 13F filing for Q2 2020, filed 14 Aug 2020.